CA2011428A1 - Utilisation de derives de 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine dans le traitement des psychoses et des inflammations et comme immunosuppresseur - Google Patents

Utilisation de derives de 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine dans le traitement des psychoses et des inflammations et comme immunosuppresseur

Info

Publication number
CA2011428A1
CA2011428A1 CA2011428A CA2011428A CA2011428A1 CA 2011428 A1 CA2011428 A1 CA 2011428A1 CA 2011428 A CA2011428 A CA 2011428A CA 2011428 A CA2011428 A CA 2011428A CA 2011428 A1 CA2011428 A1 CA 2011428A1
Authority
CA
Canada
Prior art keywords
immunosuppressants
tetrahydro
inflammation
phenyl
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2011428A
Other languages
English (en)
Other versions
CA2011428C (fr
Inventor
Billie Kenneth Koe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23244506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2011428(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of CA2011428A1 publication Critical patent/CA2011428A1/fr
Application granted granted Critical
Publication of CA2011428C publication Critical patent/CA2011428C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002011428A 1989-03-07 1990-03-05 Utilisation de derives de 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine dans le traitement des psychoses et des inflammations et comme immunosuppresseur Expired - Fee Related CA2011428C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/320,014 US4981870A (en) 1989-03-07 1989-03-07 Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
US320,014 1989-03-07

Publications (2)

Publication Number Publication Date
CA2011428A1 true CA2011428A1 (fr) 1990-09-07
CA2011428C CA2011428C (fr) 1994-11-08

Family

ID=23244506

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002011428A Expired - Fee Related CA2011428C (fr) 1989-03-07 1990-03-05 Utilisation de derives de 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine dans le traitement des psychoses et des inflammations et comme immunosuppresseur

Country Status (17)

Country Link
US (2) US4981870A (fr)
EP (1) EP0386997B1 (fr)
JP (2) JPH0714870B2 (fr)
KR (1) KR920005810B1 (fr)
AT (1) ATE150299T1 (fr)
AU (1) AU610036B2 (fr)
CA (1) CA2011428C (fr)
DE (1) DE69030212T2 (fr)
DK (1) DK0386997T3 (fr)
HU (1) HU221624B1 (fr)
IE (1) IE81047B1 (fr)
IL (1) IL93576A (fr)
MY (1) MY106272A (fr)
NZ (1) NZ232800A (fr)
PH (1) PH26542A (fr)
PT (1) PT93351B (fr)
ZA (1) ZA901743B (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
CA2071897A1 (fr) * 1989-12-28 1991-06-29 Richard A. Glennon Ligands du recepteur sigma et leur utilisation
ES2060547B1 (es) * 1992-06-04 1995-06-16 Ferrer Int Mejoras en el objeto de la patente de invencion n/ 9201158 que se refiere a "procedimiento de obtencion de nuevos derivados de la 4-bencilpiperidina".
AU7177694A (en) * 1993-06-23 1995-01-17 Cambridge Neuroscience, Inc. Sigma receptor ligands and the use thereof
ES2074946B1 (es) * 1993-07-19 1996-06-16 Ferrer Int Nuevos compuestos derivados de la 1,2-etanodiamina-n,n,n',n'-tetrasustituida.
IL133080A0 (en) 1997-07-01 2001-03-19 Pfizer Sertraline salts and sustained-release dosage forms of sertraline
US20040208926A1 (en) * 1997-07-01 2004-10-21 Pfizer Inc Solubilized sertraline compositions
US20030133974A1 (en) * 1997-07-01 2003-07-17 Curatolo William John Encapsulated solution dosage forms of sertraline
WO2001047498A2 (fr) 1999-12-23 2001-07-05 Pfizer Products Inc. Forme de dosage d'un medicament stratifie entraine par un hydrogel
CA2450073C (fr) 2001-07-25 2017-08-29 Biomarin Pharmaceutical Inc. Compositions et procedes de modulation du transport a travers la barriere hematho-encephalique
US6988556B2 (en) * 2002-02-19 2006-01-24 Halliburton Energy Services, Inc. Deep set safety valve
EP1542961B1 (fr) * 2002-09-16 2013-09-11 Sepracor, Inc. Trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine pour le traitement des troubles du systeme nerveux central
US8134029B2 (en) 2002-09-16 2012-03-13 Sunovion Pharmaceuticals Inc. Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
JP2006504693A (ja) * 2002-09-16 2006-02-09 セプラコア インコーポレーテッド トランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−ｎ−メチル−１−ナフタレンアミンによるｃｎｓ障害の治療
CN100584818C (zh) * 2002-09-16 2010-01-27 塞普拉科公司 用反式4-(3,4-二氯苯基)-1,2,3,4-四氢-1-萘胺及其甲酰胺治疗cns病症
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
NZ548212A (en) * 2003-12-29 2010-07-30 Sepracor Inc Pyrrole and pyrazole DAAO inhibitors
EP2671508B1 (fr) 2005-04-28 2020-09-16 Proteus Digital Health, Inc. Système pharma-informatique
WO2007006003A2 (fr) * 2005-07-06 2007-01-11 Sepracor Inc. Combinaisons d'eszopiclone et de trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-naphtalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphtalenamine, et methodes de traitement de la menopause et des troubles de l'humeur, de l'anxiete et troubles cognitifs
WO2007047978A2 (fr) 2005-10-21 2007-04-26 Braincells, Inc. Modulation de la neurogenese par inhibition de la pde
EP2314289A1 (fr) 2005-10-31 2011-04-27 Braincells, Inc. Modulation de la neurogenese dont la médiation est assurée par récepteur gaba
US8053603B2 (en) * 2006-01-06 2011-11-08 Sunovion Pharmaceuticals Inc. Tetralone-based monoamine reuptake inhibitors
KR101294014B1 (ko) 2006-01-06 2013-08-09 선오비온 파마슈티컬스 인코포레이티드 모노아민 재흡수 저해제로서의 시클로알킬아민
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
DK2816024T3 (en) 2006-03-31 2017-10-30 Sunovion Pharmaceuticals Inc CHIRALE AMINER
EP2021000A2 (fr) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenèse par modulation de l'angiotensine
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
AU2007254751A1 (en) * 2006-05-31 2007-12-13 Sepracor Inc. Treatment of pain disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine and its formamide
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
WO2008030651A1 (fr) 2006-09-08 2008-03-13 Braincells, Inc. Combinaisons contenant un dérivé de 4-acylaminopyridine
JP2010503710A (ja) 2006-09-18 2010-02-04 ラプトール ファーマシューティカル インコーポレイテッド 受容体関連タンパク質（ｒａｐ）結合体の投与による肝障害の処置
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
FR2909376A1 (fr) * 2006-11-30 2008-06-06 Cerep Sa Procedes de preparation de la desmethulsertraline ou d'un de ses sels pharmaceutiquement acceptables
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
US20090099248A1 (en) * 2007-01-18 2009-04-16 Sepracor Inc. Inhibitors of d-amino acid oxidase
MX2009012685A (es) 2007-05-31 2009-12-14 Sepracor Inc Cicloalquilaminas sustituidas con fenilo como inhibidores de la reabsorcion de monoamina.
WO2010017418A1 (fr) * 2008-08-07 2010-02-11 Sepracor Inc. Promédicaments d'inhibiteurs hétérocycliques fusionnés de la d-amino acide oxydase
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
KR20180114970A (ko) 2009-05-06 2018-10-19 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
WO2011017634A2 (fr) * 2009-08-07 2011-02-10 Sepracore Inc. Promédicaments d'inhibiteurs hétérocycliques fusionnés de la d-aminoacide oxydase
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
CA2904767C (fr) 2013-03-15 2022-06-21 Agenebio, Inc. Procedes et compositions pour ameliorer la fonction cognitive
US20170266133A1 (en) * 2014-05-13 2017-09-21 Sunovion Pharmaceuticals Inc. Methods and compositions of dasotraline for treatment of adhd
MX2016014768A (es) * 2014-05-13 2017-03-06 Sunovion Pharmaceuticals Inc Dosificacion de dasotralina y metodo para el tratamiento del trastorno por deficit de atencion con hiperactividad adhd.
WO2016046669A2 (fr) * 2014-09-27 2016-03-31 Mohan M Alapati Compositions et méthodes de traitement de la dépression et de maladies neurologiques
EA034167B8 (ru) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения
FR3071726B1 (fr) * 2017-09-29 2020-09-04 Univ Paris Sud Agents inhibant la proteine tctp pour le traitement de maladies proliferatives et de maladies infectieuses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1420472A (en) * 1972-09-27 1976-01-07 Pfizer Aminophenyltetralin compounds
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
JPS59497B2 (ja) * 1979-11-01 1984-01-07 フアイザ−・インコ−ポレ−テツド トランス−４−フエニル−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの抗抑うつ性誘導体
US4792448A (en) * 1987-06-11 1988-12-20 Pfizer Inc. Generic zero order controlled drug delivery system
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants

Also Published As

Publication number Publication date
PH26542A (en) 1992-08-19
KR900013949A (ko) 1990-10-22
DK0386997T3 (da) 1997-04-14
MY106272A (en) 1995-04-29
ZA901743B (en) 1991-10-30
NZ232800A (en) 1997-07-27
IL93576A (en) 1995-12-08
IL93576A0 (en) 1990-11-29
JPH02300121A (ja) 1990-12-12
EP0386997A2 (fr) 1990-09-12
JPH0714870B2 (ja) 1995-02-22
PT93351B (pt) 1996-03-29
HU221624B1 (hu) 2002-12-28
PT93351A (pt) 1990-11-07
DE69030212T2 (de) 1997-06-26
KR920005810B1 (ko) 1992-07-20
IE81047B1 (en) 1999-12-01
HU901325D0 (en) 1990-05-28
EP0386997A3 (fr) 1992-04-29
JP3020808B2 (ja) 2000-03-15
DE69030212D1 (de) 1997-04-24
CA2011428C (fr) 1994-11-08
ATE150299T1 (de) 1997-04-15
AU5079690A (en) 1990-09-20
JPH07173056A (ja) 1995-07-11
US4981870A (en) 1991-01-01
AU610036B2 (en) 1991-05-09
EP0386997B1 (fr) 1997-03-19
US5061728A (en) 1991-10-29
IE900798L (en) 1990-09-07
HUT59000A (en) 1992-04-28

Similar Documents

Publication Publication Date Title
CA2412554A1 (fr) Morphines 3-substituees
CA2151674A1 (fr) Methodes d'administration d'antagonistes du crf
CA2131683A1 (fr) Derives de stilbene et compositions pharmaceutiques en contenant
CA2067404A1 (fr) Les benzoisothiazole- et benzoisoxazole-3-carboxamides, procede pour leur preparation et leur utilisation comme medicaments
CA2146238A1 (fr) Nouveaux derives bicycliques de lactame et de mercaptoacetylamide, utiles comme inhibiteurs de l'encephalinase et de l'ace
CA2175542A1 (fr) Colorants capillaires a base d'anthraquinone, a chaine laterale d'ammonium quaternaire
CA2103838A1 (fr) 7-(substituant)-8-(substituant)-9-[(glycyle substitue)amido]-6-demethyl-6-desoxytetracyclines
CA2065523A1 (fr) Compositions herbicides
CA2189603A1 (fr) Derive de la propiophenone et methodes de preparation
CA2115536A1 (fr) Derives heterocycliquement substitues de phenyl-cyclohexane-acide carboxylique
Coulter Lake Tanganyika
CA2143756A1 (fr) N-cyano-n'-pyridylguanidines, antagonistes de la serotonine
CA2210492A1 (fr) Derives de l'acide neuraminique, leur preparation et leur utilisation medicale
CA2094012A1 (fr) 1,2,4-oxadiazolyl-phenoxyalkylisoxazoles et leur utilisation comme agents antiviraux
CA2246568A1 (fr) Phosphatidyloligoglycerines
CA2478971A1 (fr) Androstenones
JPS6422813A (en) Antiphlegmonic slimming cosmetics containing 1-hydroxyalkylxanthin
IE851734L (en) Isoindolinyl-alkyl-piperazines
IT8548000A0 (it) Complessi metalliferi 1:2 di composti azoici, loro preparazione e loro impiego come coloranti
CA2011987A1 (fr) Esters herbicides de l'acide 1,3,5-triazin-2-ylaminocarbonyla-minosulfonylbenzoiques, leur preparation et leur utilisation
AU5727899A (en) Diaminocyclobutene-3,4-dione derivatives, their preparation and use
CA2032254A1 (fr) Derives de glycerol, mode de preparation et compositions therapeutiques en contenant
CA2035499A1 (fr) Triazolopyridarines substituees
IE45556L (en) 2-[n-(cycloalkylmethyl)-n-(phenyl)-amino]-2- imidazoline¹derivatives
CA2160101A1 (fr) Compose de type metallocene

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed